2 weeks Ago By ABMN Staff
Northwestern Mutual Wealth Management Co. boosted its holdings in Thermo Fisher Scientific Inc. ( NYSE:TMO – Free Report ) by 3.
7% in the second quarter, Holdings Channel reports. The firm owned 111,706 shares of the medical research company’s stock after purchasing an additional 4,030 shares during the quarter. Northwestern Mutual Wealth Management Co.
’s holdings in Thermo Fisher Scientific were worth $61,776,000 as of its most recent SEC filing. A number of other hedge funds have also added to or reduced their stakes in the business. Brookstone Capital Management grew its position in shares of Thermo Fisher Scientific by 252.
4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after acquiring an additional 3,142 shares during the period. Leo Wealth LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $1,117,000.
Rhenman & Partners Asset Management AB grew its position in shares of Thermo Fisher Scientific by 6,600.0% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 33,500 shares of the medical research company’s stock valued at $17,781,000 after acquiring an additional 33,000 shares during the period.
BDF Gestion bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $6,368,000. Finally, Aviance Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 20.9% during the 1st quarter.
Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock worth $7,581,000 after buying an additional 2,251 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.
Insider Activity at Thermo Fisher Scientific In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.
21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.
36. The transaction was disclosed in a filing with the SEC, which is accessible through this link . In other Thermo Fisher Scientific news, CEO Marc N.
Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.
00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36.
The transaction was disclosed in a filing with the SEC, which is accessible through this link . Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, July 26th.
The stock was sold at an average price of $600.85, for a total transaction of $1,201,700.00.
Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,860,920.55. The disclosure for this sale can be found here .
Insiders have sold 23,084 shares of company stock worth $14,094,292 in the last quarter. Company insiders own 0.34% of the company’s stock.
Thermo Fisher Scientific Stock Down 0.8 % Thermo Fisher Scientific ( NYSE:TMO – Get Free Report ) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.
37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24.
Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%.
The company had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion.
During the same quarter in the previous year, the company earned $5.15 EPS. Thermo Fisher Scientific’s quarterly revenue was down 1.
4% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.
72 earnings per share for the current year. Thermo Fisher Scientific Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.
39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.
56 dividend on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s payout ratio is presently 10.
01%. Analyst Ratings Changes A number of analysts have recently issued reports on TMO shares. Barclays cut their target price on shares of Thermo Fisher Scientific from $615.
00 to $600.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. Robert W.
Baird lifted their price objective on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th.
Raymond James lifted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th.
Stifel Nicolaus raised their target price on shares of Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a report on Friday, September 20th.
Finally, Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 target price on the stock.
Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $650.
41. Get Our Latest Research Report on TMO About Thermo Fisher Scientific ( Free Report ) Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. ( NYSE:TMO – Free Report ).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter ..
